188 related articles for article (PubMed ID: 33874986)
1. Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5'-deoxy-5-fluorocytidine (5'-DFCR).
Gao Y; Zens P; Su M; Gemperli CA; Yang H; Deng H; Yang Z; Xu D; Hall SRR; Berezowska S; Dorn P; Peng RW; Schmid RA; Wang W; Marti TM
J Exp Clin Cancer Res; 2021 Apr; 40(1):138. PubMed ID: 33874986
[TBL] [Abstract][Full Text] [Related]
2. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
Shord SS; Patel SR
J Exp Clin Cancer Res; 2009 Jun; 28(1):76. PubMed ID: 19500405
[TBL] [Abstract][Full Text] [Related]
4. DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor-resistant lung cancer therapy.
Heo H; Kim JH; Lim HJ; Kim JH; Kim M; Koh J; Im JY; Kim BK; Won M; Park JH; Shin YJ; Yun MR; Cho BC; Kim YS; Kim SY; Kim M
Exp Mol Med; 2022 Aug; 54(8):1236-1249. PubMed ID: 35999456
[TBL] [Abstract][Full Text] [Related]
5. Correlation Between the Metabolic Conversion of a Capecitabine Metabolite, 5'-Deoxy-5-fluorocytidine, and Creatinine Clearance.
Inaishi T; Fujita KI; Matsumoto N; Shimokata T; Maeda O; Kikumori T; Hattori N; Nakayama G; Ando Y
In Vivo; 2020; 34(6):3539-3544. PubMed ID: 33144465
[TBL] [Abstract][Full Text] [Related]
6. Associations of cytosine deaminase gene polymorphisms with effectiveness of gemcitabine/cisplatin chemotherapy in patients of Xinjiang Uyghur and Han nationality with non-small cell lung cancer.
Li J; Xu D; Huang J; Wang YN; Ma XP; Lin ZY; Gong P
Int J Biol Markers; 2019 Dec; 34(4):389-397. PubMed ID: 31603383
[TBL] [Abstract][Full Text] [Related]
7. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.
Joerger M; Burgers JA; Baas P; Doodeman VD; Smits PH; Jansen RS; Vainchtein LD; Rosing H; Huitema AD; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2012 Jan; 69(1):25-33. PubMed ID: 21590444
[TBL] [Abstract][Full Text] [Related]
8. Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.
Tabata T; Katoh M; Tokudome S; Hosakawa M; Chiba K; Nakajima M; Yokoi T
Drug Metab Dispos; 2004 Jul; 32(7):762-7. PubMed ID: 15205393
[TBL] [Abstract][Full Text] [Related]
9. Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.
Tibaldi C; Camerini A; Tiseo M; Mazzoni F; Barbieri F; Vittimberga I; Brighenti M; Boni L; Baldini E; Gilli A; Honeywell R; Chartoire M; Peters GJ; Giovannetti E;
Br J Cancer; 2018 Nov; 119(11):1326-1331. PubMed ID: 30405211
[TBL] [Abstract][Full Text] [Related]
10. Comparison of in vitro metabolic conversion of capecitabine to 5-FU in rats, mice, monkeys and humans--toxicological implications.
Shindoh H; Nakano K; Yoshida T; Ishigai M
J Toxicol Sci; 2011 Aug; 36(4):411-22. PubMed ID: 21804305
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment.
Gao Y; Dorn P; Liu S; Deng H; Hall SRR; Peng RW; Schmid RA; Marti TM
Cancer Cell Int; 2019; 19():317. PubMed ID: 31798346
[TBL] [Abstract][Full Text] [Related]
13. Contribution of Cytidine Deaminase to Thymidylate Biosynthesis in Trypanosoma brucei: Intracellular Localization and Properties of the Enzyme.
Moro-Bulnes A; Castillo-Acosta VM; Valente M; Carrero-Lérida J; Pérez-Moreno G; Ruiz-Pérez LM; González-Pacanowska D
mSphere; 2019 Aug; 4(4):. PubMed ID: 31391279
[TBL] [Abstract][Full Text] [Related]
14. The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis.
Li H; Wang X; Wang X
Int J Biol Markers; 2014; 29(3):e224-32. PubMed ID: 24557790
[TBL] [Abstract][Full Text] [Related]
15. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer.
Yu S; Qin X; Chen T; Zhou L; Xu X; Feng J
Anticancer Drugs; 2017 Sep; 28(8):852-860. PubMed ID: 28723865
[TBL] [Abstract][Full Text] [Related]
18. Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer.
Liang SQ; Marti TM; Dorn P; Froment L; Hall SR; Berezowska S; Kocher G; Schmid RA; Peng RW
Cell Death Dis; 2015 Jul; 6(7):e1824. PubMed ID: 26181204
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
[TBL] [Abstract][Full Text] [Related]
20. CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer.
Zauri M; Berridge G; Thézénas ML; Pugh KM; Goldin R; Kessler BM; Kriaucionis S
Nature; 2015 Aug; 524(7563):114-8. PubMed ID: 26200337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
